What is REGN's five-year median P/E?

The median, or middle weekly reading, is 17.8× over the last five years. Available history contains 533 weekly observations from Aug 8, 2016 to Oct 19, 2026.

Does a low historical rank mean a stock is a buy?

No. The rank describes a stock’s own history. Changes in growth, financial risk and the business can change the multiple investors pay. P/E uses earnings and P/S uses revenue from the previous twelve months.

Regeneron Pharmaceuticals (REGN) valuation history

Within its usual range

As of Oct 22, 2026

REGN's P/E of 19.9x is higher than 67% of its available weekly readings from the last five years.

Share P/E history

Shared chart range

Preview embed

Chart by stockresearch.app. Reuse with credit under CC BY 4.0.

P/E at year-end

Last weekly reading of each completed year. Rank runs from lowest (0%) to highest (100%) within the five years available on that date.

REGN year-end valuation history
Reading date	P/E	5-year rank
Dec 29, 2025	18.6×	62%
Dec 30, 2024	17.8×	41%
Dec 25, 2023	25.1×	89%
Dec 26, 2022	15.2×	34%
Dec 27, 2021	10.1×	2%
Dec 28, 2020	17.7×	13%
Dec 30, 2019	19.8×	22%
Dec 31, 2018	25.4×	11%
Dec 25, 2017	34.2×	2%
Dec 26, 2016	53.3×	Short history

Peers on the same measure

Stock	P/E	5-year rank
ABBVAbbVie	80.5×	76%
AMGNAmgen	27.2×	78%
GILDGilead Sciences	Unavailable	Unranked
INCYIncyte	16.0×	9%

Appears in

Health Care Stocks with Low P/E Ratios and Steady Revenue Growth Stocks Below Their 5-Year Median P/E Stocks Near Their Lowest P/E Ratios in 5 Years

Research on REGN

No published research on REGN yet. Read how valuation percentiles work.

Loading related research…

About this history

What is REGN's current P/E?: REGN's P/E of 19.9x is higher than 67% of its available weekly readings from the last five years.
What is REGN's five-year median P/E?: The median, or middle weekly reading, is 17.8× over the last five years. Available history contains 533 weekly observations from Aug 8, 2016 to Oct 19, 2026.
Does a low historical rank mean a stock is a buy?: No. The rank describes a stock’s own history. Changes in growth, financial risk and the business can change the multiple investors pay. P/E uses earnings and P/S uses revenue from the previous twelve months.